The investment-grade notes are due 2028, 2030, 2035 and 2055

Davis Polk advised the representatives of the underwriters, in connection with an SEC-registered offering by AbbVie Inc. of $4 billion aggregate principal amount of senior notes in four series, consisting of $1.25 billion aggregate principal amount of 4.650% senior notes due 2028, $1 billion aggregate principal amount of 4.875% senior notes due 2030, $1 billion aggregate principal amount of 5.200% senior notes due 2035 and $750 million aggregate principal amount of 5.600% senior notes due 2055. AbbVie expects to use the net proceeds from the offering to repay outstanding debt and/or for general corporate purposes.

AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, oncology, aesthetics, neuroscience and eye care. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associate Steven Glendon. The tax team included partner Patrick E. Sigmon and associates Tyler Scheiner and Jenna Battaglia. Partner David R. Bauer and associates Ted (Edward) Talas and Anne Kim provided intellectual property advice. Counsel David A. Zilberberg provided environmental advice. All members of the Davis Polk team are based in the New York office.

 

Copy link to share post